American Samoa News

The proteome profiling services market is projected to be worth USD 16 billion by 2030, growing at a CAGR of 15%, claims Roots Analysis

The study also features a detailed analysis of the key drivers and trends related to this evolving domain.

January 11, 2021

More than 120 industry players are engaged in evaluating the potential of over 280 stem cell therapy products

Recent studies suggest that mesenchymal stem cells mesenchymal stem cells can be effectively used to improve patients' resistance to the SARS-CoV-2 virus induced pneumonia leading to speedy recovery.

January 8, 2021

With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030, claims Roots Analysis

More than 120 industry players are engaged in evaluating the potential of over 280 stem cell therapy products for the treatment of a variety of disease indications.

January 8, 2021

With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030, claims Roots Analysis

A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters

January 8, 2021

The “RNAi Therapeutics Market (2nd Edition), 2019 - 2030: Focus on siRNA, miRNA, shRNA and DNA”

An analysis of completed, ongoing and planned clinical studies for different types of RNAi molecules.

January 8, 2021

Presently, there are two approved drug and over 150 product candidates, claims Roots Analysis

There are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

January 8, 2021

RNAi Therapeutics Market is projected to grow at an annualized rate of ~45%, till 2030

Investors, having realized the opportunity within this emerging segment of the pharmaceutical industry, have invested over USD 5 billion in capital across 65 instances, in the period between 2014 and 2019

January 8, 2021

RNAi Therapeutics Market is estimated to be worth USD 9.2 billion in 2030, predicts Roots Analysis

A detailed assessment of the current market landscape of drug developers engaged in the development of RNAi therapeutics

January 8, 2021

The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, claims Roots Analysis

Around USD 3 billion was raised through secondary offerings, representing more than 50% of the total capital raised by industry players till July 2019

January 8, 2021

The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030”

Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics

January 8, 2021

Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products

The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios.

January 8, 2021

The biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~8%, till 2030

he market landscape is highly fragmented featuring the presence of both established players and new entrants; majority of biopharmaceutical CMOs are based in the developed geographies

January 8, 2021

The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis

Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.”

January 8, 2021

The ‘Biologics Fill / Finish Service Providers, 2019-2030’

An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects, in the period between 2016 and 2019 (till November),

January 8, 2021

Over 115 companies located in various regions across the globe claim to provide contract fill / finish services

Complex production protocols and special procedures and equipment for fill / finish operations. Consequently

January 8, 2021

The contract fill / finish services market for biologics market is projected to grow at an annualized rate of ~10%, till 2030

Over 115 companies located in various regions across the globe claim to provide contract fill / finish services for various types of biopharmaceutical drug / therapy products

January 8, 2021

The contract fill / finish services market for biologics is anticipated to be worth USD 4.2 billion by 2030, predicts Roots Analysis

A detailed review of the overall landscape of contract fill / finish services market for biopharmaceuticals.

January 8, 2021

The “STING Pathway Targeting Therapeutics and Technologies, 2020-2030”

The chapter also features an analysis of the developer landscape (including information on year of establishment, company size, geography and most active players).

January 8, 2021

Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies as well as in combination with other drugs

The growing popularity of this therapeutic technique has not only garnered the interest of several medical researchers (reflected in the increasing volume of scientific literature (1,000+ articles published since 2015) on this subject)

January 8, 2021

The STING pathway targeting technologies market is projected to grow at an annualized rate of ~25%, till 2030

The pipeline features candidates targeting different therapeutic areas and designed for administration through a variety of routes; majority of such therapeutics are being developed as third-line and second-line treatments

January 8, 2021

The STING pathway targeting technologies market, featuring a healthy pipeline of therapeutics, is anticipated to be worth over USD 2.8 billion by 2030

Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030

January 8, 2021

More than 100 subcutaneous biologics have been approved and over 350 such drug candidates are being evaluated in the clinical stages of development

Many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.

January 8, 2021

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

Several technology developers have out-licensed their proprietary platforms to pharmaceutical companies in order to enable them to develop subcutaneous formulations of their approved / pipeline products

January 8, 2021

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030, predicts Roots Analysis

A detailed assessment of the current market landscape of commercially available and clinical-stage biologics that are designed for delivery via the subcutaneous route

January 8, 2021

The “Targeted Protein Degradation Market, 2020-2030” report features an extensive study of the current market landscape

An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.

January 8, 2021

More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications

The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago

January 8, 2021

The targeted protein degradation market is projected to grow at an annualized rate of more than 30% till 2030

The pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routes

January 8, 2021

The “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways”

An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, posted during the period 2010-2019 (till May),

January 8, 2021

About 75 drug candidates based on synlet gene pairs are being evaluated for the treatment of various types of cancers

Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment

January 8, 2021

The synthetic lethality-based drugs and targets market is projected to grow at an annualized rate of ~18%, till 2030

An analysis of recent activity on Twitter confirms the rising interest in this domain as stakeholders attempt to harness the therapeutic potential of synthetic lethality

January 8, 2021

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030, predicts Roots Analysis

Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit

January 8, 2021